Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lolium allergen extract is a biologic preparation derived from the pollen of *Lolium perenne* (perennial ryegrass). It is used primarily for the diagnosis and immunotherapy of grass pollen-induced allergic conditions such as allergic rhinitis (hay fever) and rhinoconjunctivitis. The mechanism of action involves gradual exposure to small amounts of the allergen to induce immune tolerance, thereby reducing allergic symptoms over time. This process can increase IgG production and modulate cell-mediated immunity while decreasing immediate hypersensitivity responses. The product may be administered via subcutaneous injection for allergy testing or as sublingual tablets (notably under the brand name Oralair) for immunotherapy. Modified forms (allergoids) are sometimes used to reduce IgE binding and minimize adverse reactions[1][3][5][6][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lolium allergen extract.